

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC, INC and
PAR PHARMACEUTICAL, INC.
Petitioner

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

Case IPR2015-00547
Patent 7,765,107

**PETITIONERS' OBJECTIONS TO EVIDENCE SUBMITTED DURING THE
PRELIMINARY PROCEEDING PURSUANT TO 37 C.F.R. § 42.64(B)(1)**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §42.64(b)(1), Petitioners Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc. object as follows to the admissibility of evidence submitted during the preliminary proceeding:

1. **JAZZ EXHIBIT 2015** is objected to under Fed. R. Ev. 401–402 because the Exhibit does nothing to show that Par Pharmaceutical Holdings, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Holdings, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2015** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

2. **JAZZ EXHIBIT 2016** is objected to under Fed. R. Ev. 401–402 because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2016** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

3. **JAZZ EXHIBIT 2017** is objected to under Fed. R. Ev. 401–402 because the section of website presented does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this

proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2017** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

4. **JAZZ EXHIBIT 2018** is objected to under Fed. R. Ev. 401–402 because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2018** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

5. **JAZZ EXHIBIT 2019** is objected to under Fed. R. Ev. 401–402 because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2019** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

6. **JAZZ EXHIBIT 2020** is objected to under Fed. R. Ev. 401–402

because the Exhibit does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2020** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

7. **JAZZ EXHIBIT 2021** is objected to under Fed. R. Ev. 401–402 because the Exhibit does nothing to show that Par Pharmaceutical Holdings, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2021** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

8. **JAZZ EXHIBIT 2023** is objected to under Fed. R. Ev. 401 because the Exhibit here does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2023** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

9. **JAZZ EXHIBIT 2025** is objected to under Fed. R. Ev. 401 because the Exhibit here does nothing to show that Par Pharmaceutical Companies, Inc. has any relation, direction, or control over this proceeding, and is thus irrelevant to the question of whether Par Pharmaceutical Companies, Inc. is a real-party-in-interest in this proceeding. **JAZZ EXHIBIT 2025** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading, confusing the issues, and needlessly cumulative. **JAZZ EXHIBIT 2025** is also objected to under Fed. R. Ev. 802 as impermissible hearsay, as it is a statement offered by Jazz Pharmaceuticals, Inc. in an attempt to prove the truth of the matter asserted therein, including, but not limited to, that David Silverstein is employed by Par Pharmaceutical Companies, Inc.

10. **JAZZ EXHIBIT 2026** is objected to under Fed. R. Ev. 401–402 because the Exhibit is a Complaint is for a proceeding unrelated to the present Petition, and fails to in any way demonstrate that Par Pharmaceutical Companies, Inc. has any direction or control over the instant Petition or proceedings sufficient to make them a real party in interest. **JAZZ EXHIBIT 2026** is also objected to under Fed. R. Ev. 403 because its minimal probative value is substantially outweighed by the fact that it is misleading and needlessly cumulative.

11. **JAZZ EXHIBIT 2027** is objected to under Fed. R. Ev. 401–402 because the Exhibit is a Complaint is for a proceeding unrelated to the present

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.